Zecyte 250mg
Description
Zecyte 250 mg Tablet is an anticancer drug used in men along with Major & minor side effects for Zecyte 250 mg Tablet.
Usage Of Zecyte
The patient clinically not used for chemotherapy with prednisone or prednisolone will preferred treatment with metastatic CRPC in adult men.
Zecyte is an inhibitor of CYP17 which is used to treats the patients with metastatic castration-resistant prostate cancer, The patient have received earlier chemotherapy with docetaxel combination with prednisone and in failure of androgen deprivation treatment.
Dosage & Administration
• Zecyte tablets in Combination with prednisone 5 mg administered orally twice daily.
• Prescribed dose of Zecyte tablets is 1,000 mg, Zecyte 250mg given 4 dose orally once in a day (OD).
• Zecyte Tablets administrated on an empty stomach.
• Zecyte should be swallowed whole with water.
• Do not crush or chew the tablets.
• Zecyte Tablets administrated on an empty stomach.
• Zecyte should be swallowed whole with water.
• Do not crush or chew the tablets.
Describe as
It is an antiandrogen medication is indicated for the treatment of prostate cancer which spread to other parts of the body. Zecyte is also used along with prednisone, a steroid. In clinical trials Zecyte is used for prostate cancer and advanced breast cancer.Mechanism Of Action
Particularily , abiraterone prevents the conversion of 17-hydroxyprognenolone to dehydroepiandrosterone (DHEA) by the enzyme CYP17A1 to reduce serum levels of testosterone and other androgens.An enzyme CYP17A1 which catalyzes the biosynthesis of androgen and is highly expressed in testicular, adrenal, and prostatic tumor tissue.Drug Interaction
Drugs that inhibits or induce CYP3A4Abiraterone interaction with strong CYP3A4inhibitors or inducers, the pharmacokinetics of Abiraterone is not evaluated properily, so avoid or use with caution while abiterone therapy.
Effects of Abiraterone on drug metabolizing enzymes
Abiraterone is a hepatic drug-metabolizing inhibitor CYP2D6, when substrates (dextromethorphan) of it is co administrated with Abiraterone will increases the Cmax and AUC dextromethorphan.
Abiraterone is a hepatic drug-metabolizing inhibitor CYP2D6, when substrates (dextromethorphan) of it is co administrated with Abiraterone will increases the Cmax and AUC dextromethorphan.
For more Information
Contact us : +91- 9987711567
Email : applepharmaceutical@gmail.com
No comments:
Post a Comment